Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance...
Clinical Trial
Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from...
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company...
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy
Alleviates chemotherapy-induced neuropathyCounteracts tumor promoting signals induced by Antibody Drug Conjugate (ADC) payloadsLUND, SWEDEN / ACCESSWIRE / February 12, 2024...
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan...
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which...
Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an...
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara’s Cloudbreak platform for the development of...
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Former...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
The FDA has accepted a New Drug Application filed by Lykos Therapeutics for MDMA-assisted therapy for PTSD The application was...
CORRECTING and REPLACING Calibrate Names Rob MacNaughton as New Chief Executive Officer
MacNaughton to Lead Business into Enterprise-first EraNEW YORK--(BUSINESS WIRE)--Please replace the release dated February 8, 2024 with the following corrected...
Red Light Holland and PharmAla to Collaborate on Medical Psilocybin Development
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light Holland Toronto, Ontario--(Newsfile Corp. - February 9,...
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE...
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under...
Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing RoundRALEIGH, NC /...
Calibrate Names Rob MacNaughton as New Chief Executive Officer
MacNaughton to Lead Business into Enterprise-first Era, with OptumRx as Strategic PartnerNEW YORK--(BUSINESS WIRE)--Calibrate, the leading clinician-guided and value-based obesity...
Profound Research Charts Exciting Growth Path With Hire of CEO and Strategic Promotions of Key Leadership Roles
NASHVILLE, TN / ACCESSWIRE / February 8, 2024 / Profound Research, a leading clinical trial site network, today announced key...